retatrutide type 2 diabetes phase 2 results 2024 2025 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Retatrutide, a TRIPLE agonist (GLP1,

Protocol adherence to the SPIRIT-PRO guidelines was assessed by a single reviewer using manifest content analysis

Substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimers disease and dementia), coagulation disorders, cardiometabolic disorders (heart attack, heart failure, ischemic stroke, and hemorrhagic stroke, pulmonary embolism, pulmonary hypertension, coagulopathy and clotting disorders) chronic kidney disease, COPD, pneumonia, liver failure, inflammatory bowel disease, liver cancer) all significantly declined

2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)

Can GLP-1s Help Reduce the Risk of Cancer

High prevalence of malnutrition and micronutrient deficiencies in patients with inflammatory bowel disease early in disease course